Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man

被引:22
作者
Katagi, M [1 ]
Tatsuno, M [1 ]
Tsutsumi, H [1 ]
Miki, A [1 ]
Kamata, T [1 ]
Nishioka, H [1 ]
Nakajima, K [1 ]
Nishikawa, M [1 ]
Tsuchihashi, H [1 ]
机构
[1] Osaka Prefectural Police HQ, Forens Sci Lab, Chuo Ku, Osaka 5410053, Japan
关键词
D O I
10.1080/00498250210144857
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The metabolism of selegiline (SG) has been studied by investigating the time-course of urinary excretion of SG and its metabolites using high-performance liquid chromatography-electrospray ionization mass spectrometry (LC-ESI MS) in combination with solid-phase extraction. 2. The excretion profiles of SG and its four major metabolites, selegiline-N-oxide (SGO), N-desmethylselegiline (DM-SG), methamphetamine (MA) and amphetamine (AP), were investigated in six healthy volunteers after oral administrations of SG hydrochloride in a single dose of 2.5 or 7.5 mg, and a repeat twice-daily dose of 5.0 mg day(-1) (for 3 days). 3. The cumulative amount of SGO excreted within approximately the first 8-12 h was comparable with MA, and the amount in the first 72 h was 2.0-7.8 times larger (2.8-13.2% of the dose) than that of DM-SG. 4. These results demonstrate that SGO can be used in place of DM-SG, which is known to be a main specific metabolite of SG, as a new indicator for the discrimination of SG use compared with MA abuse.
引用
收藏
页码:823 / 831
页数:9
相关论文
共 19 条
[1]   Metabolism of N,N-dialkylated amphetamines, including deprenyl, by CYP2D6 expressed in a human cell line [J].
Bach, MV ;
Coutts, RT ;
Baker, GB .
XENOBIOTICA, 2000, 30 (03) :297-306
[2]  
BECKETT AH, 1965, J PHARM PHARMACOL, V17, P109
[3]   Studies on the Leuckart reaction [J].
Crossley, FS ;
Moore, ML .
JOURNAL OF ORGANIC CHEMISTRY, 1944, 9 (06) :529-536
[4]   ATYPICAL METABOLISM OF DEPRENYL AND ITS ENANTIOMER, (S)-(+)-N,ALPHA-DIMETHYL-N-PROPYNYLPHENETHYLAMINE BY CYTOCHROME-P450 2D6 [J].
GRACE, JM ;
KINTER, MT ;
MACDONALD, TL .
CHEMICAL RESEARCH IN TOXICOLOGY, 1994, 7 (03) :286-290
[5]   A REVIEW OF THE PHARMACOLOGY OF SELEGILINE [J].
HEINONEN, EH ;
LAMMINTAUSTA, R .
ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 :44-59
[6]   PHARMACOKINETIC ASPECTS OF L-DEPRENYL (SELEGILINE) AND ITS METABOLITES [J].
HEINONEN, EH ;
ANTTILA, MI ;
LAMMINTAUSTA, RAS .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (06) :742-749
[7]  
Hidestrand M, 2001, DRUG METAB DISPOS, V29, P1480
[8]  
JENNER P, 1971, Xenobiotica, V1, P399
[9]   Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry [J].
Katagi, M ;
Tatsuno, M ;
Miki, A ;
Nishikawa, M ;
Nakajima, K ;
Tsuchihashi, H .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2001, 759 (01) :125-133
[10]   POSSIBLE MECHANISMS OF ACTION OF (-)DEPRENYL IN PARKINSONS-DISEASE [J].
KNOLL, J .
JOURNAL OF NEURAL TRANSMISSION, 1978, 43 (3-4) :177-198